Chronopharmacokinetics of doxorubicin in patients with breast cancer


The chronopharmacokinetics of doxorubicin (DOX) has been studied in 18 patients suffering from breast cancer. They received combined chemotherapy, including DOX (50 mg/m2 as an iv bolus), given at two different times (09.00 h or 21.00 h). The two randomized courses of the protocol were given to each patient at a four week interval. The total body clearance… (More)
DOI: 10.1007/BF00315211

3 Figures and Tables


  • Presentations referencing similar topics